Reduced antiviral seropositivity among patients with inflammatory bowel disease treated with immunosuppressive agents

References

• Kucharzik T, Ellul P, Greuter T, et al. ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. J Crohns Colitis. 2021;15(6):879–913.
   PubMed Web of Science ®Google Scholar
• Kaplan LJ, Daum RS, Smaron M, et al. Severe measles in immunocompromised patients. JAMA. 1992;267(9):1237–1241.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Chaparro M. Vaccination strategies in patients with IBD. Nat Rev Gastroenterol Hepatol. 2013;10(5):277–285.
   PubMed Web of Science ®Google Scholar
• Cullen G, Baden RP, Cheifetz AS. Cheifetz as: varicella zoster virus infection in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(12):2392–2403.
   PubMed Web of Science ®Google Scholar
• Lambert N, Strebel P, Orenstein W, et al. Rubella. Lancet. 2015;385(9984):2297–2307.
   PubMed Web of Science ®Google Scholar
• Saitoh A, Okabe N. Recent progress and concerns regarding the Japanese immunization program: addressing the vaccine gap. Vaccine. 2014;32(34):4253–4258.
   PubMed Web of Science ®Google Scholar
• Saitoh A, Okabe N. Progress and challenges for the Japanese immunization program: beyond the vaccine gap. Vaccine. 2018;36(30):4582–4588.
   PubMed Web of Science ®Google Scholar
• Phadke VK, Bednarczyk RA, Salmon DA, et al. Association between vaccine refusal and vaccine-preventable diseases in the United States. JAMA. 2016;315(11):1149–1158.
   PubMed Web of Science ®Google Scholar
• Davis MM, Shah SK. Outbreaks of vaccine-preventable diseases: responding to system failure with national vaccination requirements. JAMA. 2019;322(1):33–34.
   PubMed Web of Science ®Google Scholar
• Cohen ER, Salem M, Ha C. Managing immunosuppressed patients with inflammatory bowel disease during a measles outbreak. Am J Gastroenterol. 2019;114(10):1563–1565.
   PubMed Web of Science ®Google Scholar
• Farraye FA, Melmed GY, Lichtenstein GR, et al. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017;112(2):241–258.
   PubMed Web of Science ®Google Scholar
• Naganuma M, Nagahori M, Fujii T, et al. Poor recall of prior exposure to varicella zoster, rubella, measles, or mumps in patients with IBD. Inflamm Bowel Dis. 2013;19:418–422.
   PubMed Web of Science ®Google Scholar
• Kopylov U, Levin A, Mendelson E, et al. Prior varicella zoster virus exposure in IBD patients treated by anti-TNFs and other immunomodulators: implications for serological testing and vaccination guidelines. Aliment Pharmacol Ther. 2012;36(2):145–150.
   PubMed Web of Science ®Google Scholar
• Cagol L, Seitel T, Ehrenberg S, et al. Vaccination rate and immunity of children and adolescents with inflammatory bowel disease or autoimmune hepatitis in Germany. Vaccine. 2020;38(7):1810–1817.
   PubMed Web of Science ®Google Scholar
• Lamb CA, Kennedy NA, Raine T, IBD guidelines eDelphi consensus group, et al. British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1–s106.
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Rawsthorne P, Blanchard JF. Population-based case-control study of measles, mumps, and rubella and inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:759–762.
   PubMed Web of Science ®Google Scholar
• Cleveland NK, Rodriquez D, Wichman A, et al. Many inflammatory bowel disease patients are not immune to measles or pertussis. Dig Dis Sci. 2016;61(10):2972–2976.
   PubMed Web of Science ®Google Scholar
• Caldera F, Misch EA, Saha S, et al. Immunosuppression does not affect antibody concentrations to measles, mumps, and rubella in patients with inflammatory bowel disease. Dig Dis Sci. 2019;64(1):189–195.
   PubMed Web of Science ®Google Scholar
• DeBruyn JCC, Soon IS, Fonseca K, et al. Serologic status of routine childhood vaccines, cytomegalovirus, and Epstein-Barr virus in children with inflammatory bowel disease. Inflamm Bowel Dis. 2019;25(7):1218–1226.
   PubMed Web of Science ®Google Scholar
• Boccalini S, Bechini A. Is it time to reconsider measles, mumps, and rubella immunisation strategies? Lancet Infect Dis. 2021;21(2):160–161.
   PubMed Web of Science ®Google Scholar
• Matsuoka K, Kobayashi T, Ueno F, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53(3):305–353.
   PubMed Web of Science ®Google Scholar
• Fuse N, Sakurai-Yageta M, Katsuoka F, et al. Establishment of integrated biobank for precision medicine and personalized healthcare: the Tohoku medical megabank project. Jma J. 2019;2(2):113–122.
   PubMedGoogle Scholar
• Minegishi N, Nishijima I, Nobukuni T, et al. Biobank establishment and sample management in the Tohoku medical megabank project. Tohoku J Exp Med. 2019;248(1):45–55.
   PubMed Web of Science ®Google Scholar
• Kawano Y, Suzuki M, Kawada J, et al. Effectiveness and safety of immunization with live-attenuated and inactivated vaccines for pediatric liver transplantation recipients. Vaccine. 2015;33(12):1440–1445.
   PubMed Web of Science ®Google Scholar
• Hanaoka M, Hisano M, Watanabe N, et al. Changes in the prevalence of the measles, rubella, varicella-zoster, and mumps virus antibody titers in Japanese pregnant women. Vaccine. 2013;31(19):2343–2347.
   PubMed Web of Science ®Google Scholar
• Shiga H, Abe I, Onodera M, et al. Serum C-reactive protein and albumin are useful biomarkers for tight control management of crohn’s disease in Japan. Sci Rep. 2020;10(1):511.
   PubMed Web of Science ®Google Scholar
• Kennedy NA, Lin S, Goodhand JR, et al. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut. 2021;70(10):1884–1893.
   PubMed Web of Science ®Google Scholar
• Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, et al. Lower serologic response to COVID-19 mRNA vaccine in patients with inflammatory bowel diseases treated with anti-TNFα. Gastroenterology. 2022;162(2):454–467.
   PubMed Web of Science ®Google Scholar
• Caldera F, Knutson KL, Saha S, et al. Humoral immunogenicity of mRNA COVID-19 vaccines among patients with inflammatory bowel disease and healthy controls. Am J Gastroenterol. 2022;117(1):176–179.
   PubMed Web of Science ®Google Scholar
• Alexander JL, Kennedy NA, Ibraheim H, et al. COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. Lancet Gastroenterol Hepatol. 2022;7(4):342–352.
   PubMed Web of Science ®Google Scholar
• Shiga H, Kakuta Y, An K, et al. Response to COVID-19 vaccine is reduced in patients with inflammatory bowel disease, but improved with additional dose. J Gastroenterol Hepatol. 2022. Online ahead of print.
   Web of Science ®Google Scholar
• Caldera F, Hayney MS, Farraye FA. Vaccination in patients with inflammatory bowel disease. Am J Gastroenterol. 2020;115(9):1356–1361.
   PubMed Web of Science ®Google Scholar